MoonLake Immunotherapeutics (MLTX) AI Stock Analysis

• Market Cap: $2.30B
• Dividend Yield: N/A
• Average Volume (3M): 472.11K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.53
• Revenue Growth: N/A
• EPS Growth: -147.80%
• Country: US
• Employees: 100
• Sector: Healthcare
• Sector Strength: 74
• Industry: Biotechnology
• EPS (TTM): -1.89
• Shares Outstanding: 63,282,726
• 10 Day Avg. Volume: 589,678
• 30 Day Avg. Volume: 472,107
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -13.30
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $77.44
• Price Target Upside: 115.23% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 12

MoonLake Immunotherapeutics, being a biotech company in the pre-revenue phase, faces significant financial and operational challenges, reflected in its low financial performance score. The stock's bearish technical indicators and negative valuation metrics further contribute to the overall low score. However, the recent substantial financing agreement is a positive corporate event, enhancing its financial stability and growth prospects, slightly balancing the overall score.

Positive Factors

Capital Access

MLTX announced access to non-dilutive capital of up to $500mn via a newly secured credit facility.

Clinical Trial Progress

MLTX announced the initiation of three studies of IL-17A/F nanobody sonelokimab (SLK) in adolescent patients with hidradenitis suppurativa (HS), palmoplantar pustulosis (PPP), and axial spondyloarthritis (axSpA), which is seen as positive progress in expanding the market opportunity for SLK.

Financial Position

MLTX's strong balance sheet, with end of 3Q24 cash of $493.9M and a guided runway to YE26, should provide solid support for continued clinical development activities.

Negative Factors

Clinical Trial Risks

The biggest hurdle in adolescent patients is safety, and optimism in SLK is based on a strong safety profile shown in clinical studies.

MoonLake Immunotherapeutics Business Overview & Revenue Model

Company Description

MoonLake Immunotherapeutics (MLTX) is a biotechnology company focused on developing innovative therapies for inflammatory diseases. The company leverages its proprietary nanobody technology to create targeted, potent, and effective treatments aimed at improving patient outcomes. MoonLake's core products include a pipeline of therapeutic candidates designed to address conditions such as dermatological, rheumatological, and gastroenterological diseases.

How the Company Makes Money

MoonLake Immunotherapeutics makes money primarily through the development and commercialization of its proprietary drug candidates. The company generates revenue by advancing its therapeutic products through clinical trials and ultimately seeking regulatory approval for marketing and sales. Additionally, MoonLake may engage in strategic partnerships or collaborations with other pharmaceutical companies, which can include licensing agreements, joint ventures, or co-development opportunities to enhance its product pipeline and expand market reach. These partnerships can provide upfront payments, milestone payments, and royalties, contributing to the company's overall revenue. Furthermore, MoonLake might receive funding through grants, public offerings, or private investments to support its research and development activities.

MoonLake Immunotherapeutics Financial Statement Overview

Summary

MoonLake Immunotherapeutics is in an early-stage, pre-revenue phase, typical for biotech firms. The company's financials show a strong balance sheet due to equity funding, but the lack of revenue and negative cash flows highlight its reliance on future product success and financing.

Income Statement

MoonLake Immunotherapeutics reported zero revenue over the past years, indicating a lack of commercialized products or services. This absence of revenue leads to an inability to calculate standard profitability metrics like Gross Profit Margin and Net Profit Margin. The persistent negative net income highlights ongoing operational losses, typical for a biotech company in its development phase.

Balance Sheet

The company's balance sheet shows a robust stockholders' equity position with a low level of debt, leading to a strong equity ratio. The Debt-to-Equity ratio is also favorable, indicating low financial leverage. However, the absence of revenue raises concerns about the sustainability of its equity and asset base without future revenue streams.

Cash Flow

The company exhibits significant negative free cash flow, which is typical for a biotech firm in the R&D phase. Financing activities have been substantial, suggesting reliance on external funding. However, the negative operating cash flow indicates the current lack of cash-generating operations, posing a risk if financing sources decline.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00
	Gross Profit
0.00	-13.16K	-12.36K	-4.97K	0.00
	EBIT
0.00	-54.12M	-65.06M	-53.58M	-105.76K
	EBITDA
0.00	-54.11M	-65.05M	-53.63M	-90.84K
	Net Income Common Stockholders
-120.68B	-36.01M	-64.51M	-53.64M	-90.84K
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
448.03B	511.01M	72.11M	8.04M	1.34M
	Total Assets
477.93B	526.54M	76.84M	9.68M	116.63M
	Total Debt
2.83M	3.81M	282.58K	15.00M	58.06K
	Net Debt
-177.60M	-447.36M	-39.22M	6.96M	-1.28M
	Total Liabilities
24.54B	13.05M	8.08M	21.33M	4.15M
	Stockholders Equity
446.83B	495.68M	48.90M	-11.65M	112.48M
Cash Flow		Free Cash Flow
-117.11B	-43.06M	-55.91M	-35.23M	-316.69K
	Operating Cash Flow
-116.59B	-42.78M	-55.89M	-35.18M	-316.69K
	Investing Cash Flow
-205.60B	-25.18M	-32.34M	-50.71K	-115.00M
	Financing Cash Flow
51.31B	479.70M	119.69M	43.26M	116.65M

MoonLake Immunotherapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 35.98
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MLTX, the sentiment is Negative. The current price of 35.98 is below the 20-day moving average (MA) of 38.11, below the 50-day MA of 40.53, and below the 200-day MA of 46.53, indicating a bearish trend. The MACD of -0.91 indicates Negative momentum. The RSI at 35.50 is Neutral, neither overbought nor oversold. The STOCH value of 25.34 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MLTX.

MoonLake Immunotherapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FOLD	61 Neutral	$2.12B	―	-31.68%	―	32.29%	64.39%
APLS	50 Neutral	$2.46B	―	-93.55%	―	97.02%	64.32%
Sector *	48 Neutral	$6.36B	1.28	-45.04%	2.64%	19.24%	1.69%
CRNX	45 Neutral	$2.57B	―	-32.02%	―	―	-0.12%
IBRX	39 Underperform	$2.29B	―	78.99%	―	2270.58%	46.82%
MLTX	37 Underperform	$2.30B	―	-25.24%	―	―	-147.80%
IMVT	37 Underperform	$2.53B	―	-74.17%	―	―	-43.10%

MoonLake Immunotherapeutics Corporate Events

MoonLake Immunotherapeutics Secures $500M Financing for Growth

On March 31, 2025, MoonLake Immunotherapeutics entered into a loan and security agreement with Hercules Capital for up to $500 million in non-dilutive financing. This agreement, which includes a $75 million initial draw, aims to support the company’s growth, including the advancement of sonelokimab and its expected launch in 2027. The financing enhances MoonLake’s financial position, allowing it to progress its clinical trials and prepare for commercial readiness without diluting shareholder equity. The company plans to provide further updates on its clinical programs and financial strategies at a Capital Markets Update on April 29, 2025.